HK1115387A1 - - Google Patents

Info

Publication number
HK1115387A1
HK1115387A1 HK08105362.1A HK08105362A HK1115387A1 HK 1115387 A1 HK1115387 A1 HK 1115387A1 HK 08105362 A HK08105362 A HK 08105362A HK 1115387 A1 HK1115387 A1 HK 1115387A1
Authority
HK
Hong Kong
Prior art keywords
methods
diazines
analogs
compounds
potent
Prior art date
Application number
HK08105362.1A
Other languages
English (en)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of HK1115387A1 publication Critical patent/HK1115387A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08105362.1A 2005-03-02 2008-05-14 HK1115387A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
PCT/US2006/007143 WO2006093993A1 (en) 2005-03-02 2006-03-02 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Publications (1)

Publication Number Publication Date
HK1115387A1 true HK1115387A1 (ja) 2008-11-28

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105362.1A HK1115387A1 (ja) 2005-03-02 2008-05-14

Country Status (22)

Country Link
US (1) US7875599B2 (ja)
EP (2) EP2206719B1 (ja)
JP (2) JP5130453B2 (ja)
KR (1) KR101380959B1 (ja)
CN (2) CN101155823A (ja)
AT (1) ATE482969T1 (ja)
AU (1) AU2006218711B2 (ja)
BR (1) BRPI0607523A2 (ja)
CA (1) CA2599953C (ja)
DE (1) DE602006017175D1 (ja)
DK (2) DK2206719T3 (ja)
EA (1) EA019560B1 (ja)
ES (2) ES2353413T3 (ja)
HK (1) HK1115387A1 (ja)
IL (3) IL185608A (ja)
MX (1) MX2007010593A (ja)
NZ (1) NZ561571A (ja)
PL (2) PL2206719T3 (ja)
PT (2) PT1853619E (ja)
SI (2) SI1853619T1 (ja)
WO (1) WO2006093993A1 (ja)
ZA (1) ZA200708106B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
DK2206719T3 (en) 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
CA2726734C (en) 2007-06-06 2014-10-07 University Of Maryland, Baltimore Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
WO2009114658A2 (en) * 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
JP2012506906A (ja) * 2008-10-28 2012-03-22 バイオマリン ファーマシューティカル インコーポレイテッド デカヒドロ−１ｈ−インデノキノリンおよびデカヒドロ−３ｈ−シクロペンタフェナントリジノンｃｙｐ１７インヒビター
JP2012516900A (ja) * 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ，インク． ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
GB2479693B (en) * 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
GB2514957A (en) * 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
AU2010279398A1 (en) 2009-08-07 2012-03-08 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
JP5956928B2 (ja) * 2009-11-13 2016-07-27 トーカイ ファーマシューティカルズ，インク． 哺乳類のステロイドの代謝物質
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
AU2011343637A1 (en) * 2010-12-16 2013-05-30 Biomarin Pharmaceutical Inc. C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
BR112013027395A2 (pt) 2011-04-28 2017-01-17 Novartis Ag inibidores de 17alfa-hidroxilase/c17,20-liase
WO2013012959A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
JP2015503508A (ja) * 2011-12-22 2015-02-02 トーカイ ファーマシューティカルズ，インク． ＰＩ３Ｋ／ｍＴＯＲ阻害剤を使用する併用療法のための方法および組成物
WO2014153215A1 (en) 2013-03-14 2014-09-25 University Of Maryland,Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
CA2908577C (en) 2013-04-04 2022-05-31 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
JP2016528252A (ja) * 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
PE20161405A1 (es) 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
ES2700901B2 (es) * 2016-08-08 2019-08-06 Ind Chimica Srl Proceso para la preparación de 3ß-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno.
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
WO2019160890A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (ja) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
KR101192136B1 (ko) 2003-07-29 2012-10-16 돔페 파르마 에스.피.에이. 혈액 줄기 세포의 동원에 유효한 ｇ-ｃｓｆ와 ｐｌｇｆ의조합 약제
DK2206719T3 (en) 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN

Also Published As

Publication number Publication date
EP1853619B1 (en) 2010-09-29
US7875599B2 (en) 2011-01-25
ES2528055T3 (es) 2015-02-03
IL185608A (en) 2016-06-30
ES2353413T3 (es) 2011-03-01
EA019560B1 (ru) 2014-04-30
DE602006017175D1 (de) 2010-11-11
DK2206719T3 (en) 2015-01-26
AU2006218711B2 (en) 2010-11-11
PT1853619E (pt) 2011-01-03
KR20070120119A (ko) 2007-12-21
DK1853619T3 (da) 2011-01-10
EP2206719A2 (en) 2010-07-14
EP2206719B1 (en) 2014-10-22
JP5130453B2 (ja) 2013-01-30
JP5613206B2 (ja) 2014-10-22
EP1853619A4 (en) 2009-08-26
IL185608A0 (en) 2008-01-06
CA2599953C (en) 2013-08-13
NZ561571A (en) 2009-09-25
ATE482969T1 (de) 2010-10-15
WO2006093993A1 (en) 2006-09-08
EA200701872A1 (ru) 2008-06-30
MX2007010593A (es) 2008-02-20
EP2206719A3 (en) 2011-01-05
JP2008536807A (ja) 2008-09-11
ZA200708106B (en) 2008-12-31
CN101155823A (zh) 2008-04-02
US20080280864A1 (en) 2008-11-13
EP1853619A1 (en) 2007-11-14
BRPI0607523A2 (pt) 2009-09-08
AU2006218711A1 (en) 2006-09-08
PL2206719T3 (pl) 2015-03-31
SI1853619T1 (sl) 2011-01-31
PT2206719E (pt) 2015-02-05
PL1853619T3 (pl) 2011-03-31
IL210480A0 (en) 2011-03-31
IL210478A0 (en) 2011-03-31
CN103349664A (zh) 2013-10-16
JP2012255026A (ja) 2012-12-27
SI2206719T1 (sl) 2015-03-31
IL210480A (en) 2015-06-30
AU2006218711A2 (en) 2006-09-08
KR101380959B1 (ko) 2014-04-04
CA2599953A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
HK1115387A1 (ja)
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
TW200833695A (en) Use of spiro-oxindole compounds as therapeutic agents
EP2044961A3 (en) Phospholipid analogues for the treatment of cancers
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008083252A3 (en) Methods of use for cyclopamine analogs
WO2007087548A3 (en) Chemical compounds
MX2009004096A (es) Metabolitos de talarozol.
EP1827375A4 (en) SYSTEM FOR IMPROVED PERCUTANEOUS USE OF SKIN USEFUL AGENTS
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
TW200833698A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
WO2004012682A3 (en) 2-heterosubstituted 3-aryl-4-h-1-benzopyran-4-ones as novel therapeutics in breast cancer
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200504044A (en) Methods for preparing derivatives of fungicidal iodochromones and intermediate compounds
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM UNIVERSITY OF MARYLAND TO UNIVERSITY OF MARYLAND, BALTIMORE

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180302